Introduction: Pathologic accumulation and activation of mast cells and eosinophils are implicated in allergic and inflammatory diseases. Sialic acid-binding immunoglobulinlike lectin (Siglec)-8 is an inhibitory receptor selectively expressed on mast cells, eosinophils and, at a lower extent, basophils. When engaged with an antibody, Siglec-8 can induce apoptosis of activated eosinophils and inhibit mast cell activation. AK002 is a humanized, non-fucosylated IgG1 anti-Siglec-8 antibody undergoing clinical investigation for treatment of allergic, inflammatory, and proliferative diseases. Here we examine the human tissue selectivity of AK002 and evaluate the in vitro, ex vivo, and in vivo activity of AK002 on eosinophils and mast cells. Methods: The affinity of AK002 for Siglec-8 and CD16 was determined by biolayer interferometry. Ex vivo activity of AK002 on human eosinophils from blood and dissociated human tissue was tested in apoptosis and antibody-dependent cell-mediated cytotoxicity (ADCC) assays. The in vivo activity of a murine precursor of AK002 (mAK002) was tested in a passive systemic anaphylaxis (PSA) humanized mouse model. Results: AK002 bound selectively to mast cells, eosinophils and, at a lower level, to basophils in human blood and tissue and not to other cell types examined. AK002 induced apoptosis of interleukin-5-activated blood eosinophils and demonstrated potent ADCC activity against blood eosinophils in the presence of natural killer cells. AK002 also significantly reduced eosinophils in dissociated human lung tissue. Furthermore, mAK002 prevented PSA in humanized mice through mast cell inhibition. Conclusion: AK002 selectively evokes potent apoptotic and ADCC activity against eosinophils and prevents systemic anaphylaxis through mast cell inhibition.
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Introduction
Accumulation and inappropriate activation of mast cells and eosinophils are associated with pathogenesis of many allergic and inflammatory conditions. In addition to being primary effector cells in allergic responses, mast cells and eosinophils typically co-localize at sites of chronic allergic inflammation, communicating via soluble mediators and physical contact to sustain inflammation and exacerbate disease. Despite their prominent role in the pathogenesis of multiple inflammatory diseases, to date, no single therapeutic approach directly targets both cell types.
Sialic acid-binding immunoglobulin-like lectin (Siglec)-8 is an inhibitory receptor of the CD33-related subfamily of Siglecs and found only in humans and some primates [1] [2] [3] . Siglec-8 expression is restricted to mature mast cells, eosinophils and, to a much lower extent, basophils [2] . When engaged with an anti-Siglec-8 monoclonal antibody (mAb), Siglec-8 induces apoptosis of cytokine-activated eosinophils and inhibits mast cell activation [4, 5] . Activation of eosinophils with pro-inflammatory cytokines sensitizes eosinophils to apoptosis-inducing effects of anti-Siglec-8 antibodies. Several inflammatory cytokines enhance sensitivity to anti-Siglec-8-mediated killing, including interleukin (IL)-5, granulocyte-macrophage colony stimulating factor (GM-CSF), and IL-33 [5] [6] [7] [8] . In contrast to their effect on eosinophils, anti-Siglec-8 mAbs do not induce apoptosis in resting or activated mast cells [4] . Instead, they inhibit IgE-mediated degranulation and de novo synthesis of prostaglandin D2 in vitro [4] .
Here we characterize the selectivity of Siglec-8 on human primary tissues and the mechanism of action of AK002, a novel humanized anti-Siglec-8 IgG1 antibody under therapeutic investigation in allergic and inflammatory diseases.
Materials and Methods

Human Siglec Cross-Reactivity Enzyme-Linked Immunosorbent Assay
Recombinant human Siglecs 1-3, 5-7, 9-11, and 14 proteins were purchased from R&D Systems, Siglec-4 was purchased from Sino Biological, Siglec-12 was purchased from Origene, and Siglec-8 was produced at Allakos Inc. Maxisorp TM (Thermo Fisher Scientific) immunoassay microplates were coated with human Siglec proteins (0.1 mL of 0.2 μg/mL for each protein diluted in Trisbuffered saline [50 mM Tris-Cl, pH 7.6, 150 mM NaCl]). The enzyme-linked immunosorbent assay (ELISA) plates were sealed and incubated overnight at 4 ° C. The following day, plates were washed 4 times with 0.3 mL per well of phosphate-buffered saline (PBS) with Tween-20 (PBST; PBS [137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4]) plus 0.1% v/v Tween-20. The plates were blocked with 0.3 mL of blocking buffer (2% bovine serum albumin (BSA) in PBST) and placed on a shaker set to 650 revolutions per minute (RPM) for 1 h at room temperature. The blocking buffer was removed by washing and 0.1 mL of AK002 (2 μg/mL; Allakos, Inc.); 1 μg/mL mouse anti-DYKDDDDK epitope (DDK) was added to wells that contained DDK-tagged Siglec proteins in coating control wells. All other wells received the equivalent volume of blocking buffer. The plates were then incubated at room temperature for 2 h with shaking. The plates were then washed and secondary antibody or horseradish peroxidase (HRP) conjugates were added as follows: 0.5 μg/mL of goat antihuman F(ab')2-HRP or donkey anti-mouse (heavy and light chain [H+L])-HRP were added to AK002 antibody wells; 0.1 mL of 0.5 μg/mL donkey anti-human IgG (H+L)-HRP was added for Fc-tagged Siglecs; 0.5 μg/mL of donkey anti-mouse IgG (H+L)-HRP polyclonal antibody was added for mouse anti-DDK mAb wells; or 2 μg/mL of mouse anti-His HRP mAb was added for 6xHis-tagged Siglecs. The plates were then incubated for 1 h at room temperature with shaking. Plates were then washed with PBST and 0.1 mL of tetramethylbenzidine substrate (Sigma-Aldrich) was added to each well. After 2 min, the reaction was terminated by adding 0.1 mL 1 M sulfuric acid. The converted substrate was detected in a spectrophotometer at 450 nm.
Blood and Tissue Samples
Human blood was processed by lysing red blood cells with ammonium-chloride-potassium buffer and washed in PBS (Thermo Fisher Scientific) to obtain peripheral blood leukocytes (PBL). PBL were resuspended in RPMI 1640 medium + 10% fetal bovine serum (FBS), (Thermo Fisher Scientific). Fresh human lung and skin tissues were procured and provided by the NCI Cooperative Human Tissue Network from subjects with no previous history of chronic lung disease. Other investigators may have received specimens from the same tissue specimens. Human tissue was enzymatically and mechanically dissociated using the gentleMACs TM Dissociator (Miltenyi Biotec), according to manufacturer's protocol. Tissue was minced into 2 mm pieces and incubated at 37 ° C for 1 h in digestion solution containing proprietary enzymes. Before, during, and after incubation, tissue was mechanically disrupted and run through a 70-micron filter to obtain single cells. Cells were then treated with RBC lysing buffer, washed in PBS, and resuspended in RPMI 1640 + 10% Low IgG FBS. Immediately after digestion, cell viability was examined using flow cytometry. Only single-cell suspensions from dissociated tissue that had at least 70% viability were used in subsequent experiments.
Flow Cytometry Analysis in Blood and Tissue
Approximately 0.1-0.5 × 10 6 cells/well were incubated in 96-well plates with Human Fc Block TM (BD Biosciences) for 10 min at 4 ° C followed by staining with conjugated antibodies for 10 min at 4 ° C. Cells were then washed with FACS buffer (0.1% BSA in PBS), resuspended in fixative (1% paraformaldehyde in PBS), and analyzed on a NovoCyte flow cytometer (Acea Biosciences). A minimum 100,000 events/sample were collected for each experiment. Antibodies and gating strategies are further described in the online supplementary Materials (for all online suppl. material, see www. karger.com/doi/10.1159/000501637). 6 cells were plated/well in 96-well U-bottom plates with either 1 µg/mL AK002 or non-fucosylated hIgG1 isotype control antibodies (Allakos, Inc.) followed by overnight incubation at 37 ° C. After overnight incubation, live eosinophils were identified (blood eosinophils: CD45+ 7AAD-CD16-CCR3+; tissue eosinophils: CD45+ 7AAD-SSCHi CD16-CCR3+) and quantified by flow cytometry. The percent of eosinophils remaining was calculated by normalizing the percent of CD45+ eosinophils in the isotype control treated wells to 100%.
AK002 Depletes Human Eosinophils and
Monovalent and Bivalent Affinity Determination
Binding affinities of fragment antigen-binding (Fabs) and IgG for Siglec-8 extracellular domain (ECD) were measured by biolayer interferometry using a FortéBio Octet Red 384 instrument at 25 ° C at 1,000 rpm in 1× kinetics buffer (HEPES-buffered saline; GE Healthcare) in ultrapure water, with added stabilizer (FortéBio). Fabs or IgGs were diluted from 12.5 to 0.78 nM in assay buffer in a 2-fold dilution series. Siglec-8 ECD polyethylene glycol biotinylated protein (Allakos, Inc., San Carlos, CA, USA) was immobilized on streptavidin sensors at 100 nM in 1× kinetics buffer for 3 min until a sensor change of approximately 1.8 nm was achieved. The association phase was 2 min followed by a 10-min dissociation phase. An empty reference cell sensor was used as a blank control, and affinities analyzed using FortéBio analysis software with 1: 1 global fit parameters. See online supplementary Materials for details.
Apoptosis Assay
Human eosinophils were purified (see online suppl. Material) and cultured overnight in 50 ng/mL of IL-5. Cells were then seeded in 96-well flat-bottom tissue culture plates at 50,000 eosinophils/well. AK002, AK002-G4, non-fucosylated hIgG1 isotype control, or hIgG4 isotype control antibodies (Allakos, Inc.) were added in a 10-fold dilution series between 10 μg/mL and 1 pg/mL in the presence of 50 ng/mL IL-5. Cells were cultured overnight at 37 ° C in 5% CO 2 . Following overnight incubation, cells were stained with 7AAD and Annexin V-PE (BD Biosciences) for 30 min at room temperature in the dark. The labeled eosinophils were analyzed by flow cytometry, and percentage of Annexin V-positive eosinophils was determined.
Antibody-Dependent Cell-Mediated Cytotoxicity Assay
Human eosinophils were purified (see online suppl. Material) and seeded in 96-well U-bottom tissue culture plates at 50,000 eosinophils/well. Purified human natural killer (NK) cells (AllCells) were washed with culture medium and added at 450,000 cells/well (effector: target cell ratio 9: 1). Plates were incubated for 4 h at 37 ° C in 5% CO 2 for the induction of antibody-dependent cell-mediated cytotoxicity (ADCC) activity. After incubation, the plates were centrifuged at 300 g for 2 min, and 50 μL of supernatant was removed from each well for assay of lactate dehydrogenase to determine potential ADCC activity of the treatment antibodies. Lactate dehydrogenase assays were performed as follows: to each supernatant, 50 µL CytoTox96 Assay reagent (Promega, Madison, WI, USA) was added and incubated for 30 min at room temperature. At the end of color development, 50 µL Stop Solution (Thermo Fisher Scientific) was added, and the absorbance (optical density [OD] 495 nm) was determined. As a control, 20 µL of 10× cell lysis buffer (Promega) was added to an aliquot of cells to determine maximal lysis. Percent cell death was calculated for each antibody in replicate wells by dividing each sample's OD value by the OD value for 100% eosinophil lysis.
Passive Systemic Anaphylaxis Model
Passive systemic anaphylaxis (PSA) was induced using chimeric human (ch) IgE mAb as previously described [9] . NSG-SGM3 BLT mice (see online suppl. Material) were intravenously dosed with either 100 μg mouse IgG1 isotype control mAb (Eureka Therapeutics) or the mouse precursor of AK002 (mAK002; Allakos, Inc.). Then, 24 h later NSG-SGM3 BLT mice were primed with intravenous injection of 1.6 µg of ch IgE-anti-hapten 4-hydroxy-3 nitrophenacetyl (NP) antibody (Biosearch Technologies) in 200 µL and anaphylaxis was initiated 24 h later by intravenous injection of 500 µg of NP-conjugated BSA in 100 µL of PBS. Anaphylaxis was defined as a significant decrease in core body temperature and observable symptom scores as described and adapted from Ganeshan et al. [10] and Li et al. [11] . Two blinded investigators assessed symptom scores.
Results
AK002 Binds Specifically to Siglec-8 and Interacts with CD16a
AK002 is a humanized non-fucosylated IgG1 antibody with the binding specificity of the mouse anti-Siglec-8 mAb 2E2 [5] [6] [7] . Using a panel of human Siglec proteins, AK002 bound specifically to the ECD of Siglec-8 and did not show detectable cross-reactivity with other recombinant Siglec ECDs by ELISA (Fig. 1a) . Kinetics for AK002 binding to recombinant Siglec-8 ECD were analyzed by biolayer interferometry. The binding affinity of a monovalent AK002 Fab was determined to be 464 pM, and the bivalent avidity of AK002 was < 1 pM (Fig. 1b, c ). To determine whether AK002 has high affinity for CD16 (FcγRIII), as described for other non-fucosylated IgG1 antibodies [12, 13] , CD16a and CD16b binding assays were performed by biolayer interferometry. The Fc region of AK002 had minimal interaction with immobilized CD16b, whereas the affinity of the Fc region of AK002 for immobilized CD16a (158V variant) was determined to be 9.88 nM (online suppl. Fig. S1a, b) , consistent with previous reports of the affinity of non-fucosylated IgG1 antibodies for CD16a [12] [13] [14] . In contrast, a human IgG4 version of AK002 (AK002-G4), with identical variable regions to AK002 and similar bivalent avidity to Siglec-8 ECD (online suppl. Fig. S1c ), did not have detectable affinity for CD16a (online suppl. Fig.  S1d) .
Next, we studied binding of AK002 to CD16a and Siglec-8 on human NK cells, T cells, eosinophils, and other immune cells from peripheral blood (online suppl. Fig. S1e ). Both AK002 and AK002-G4 bound similarly to eosinophils, whereas only AK002 bound to NK cells (Fig. 1d) . In contrast, no binding was observed on T cells, neutrophils, monocytes, or B cells, and very minimal binding was observed on basophils ( Fig. 1d ; online suppl. Fig. S2a ). In human PBL, AK002 showed dosedependent binding to eosinophils, whereas binding to NK cells was only detectable at higher concentrations, consistent with the relative affinities of AK002 for Siglec-8 and recombinant CD16a (Fig. 1e) . Additionally, AK002-F(ab') 2 , which lacks an Fc region, bound only to eosinophils but not NK cells or T cells (online suppl. Fig.  S2b ). These data demonstrate that AK002 binds with high affinity to Siglec-8 in vitro, to Siglec-8 expressed on eosinophils, and to NK cells via its Fc region in human blood.
Selective Binding of AK002 to Eosinophils in Human Peripheral Blood
To evaluate the selectivity of AK002, we used AK002-G4 instead of AK002 to avoid Fc-mediated binding to CD16a-expressing cells. Human peripheral blood was analyzed using multi-color flow cytometry to identify immune cell populations that express Siglec-8 (Fig. 2a) . Consistent with previously published literature using murine anti-Siglec-8 mAbs [1, 2] , AK002-G4 binding was observed only on eosinophils and, at much lower levels, on basophils (Fig. 2b, c) . AK002-G4 did not bind blood neutrophils, monocytes, B cells, T cells, or NK cells (Fig. 2b, c ; online suppl. Fig. S2c ). The robust expression of Siglec-8 on eosinophils was further confirmed using a commercially available anti-Siglec-8 mAb (online suppl. S2d ). Immune cells that stained positive for Siglec-8 using AK002-G4 (Fig. 2b) were further analyzed by flow cytometry to estimate Siglec-8 receptor density using the antibody-binding capacity of an anti-Siglec-8 antibody. Peripheral blood eosinophils had an average anti-Siglec-8 binding capacity of ∼18,000 per cell, compared with only ∼550 per cell for basophils (Fig. 2d) .
Selective Binding of AK002 to Eosinophils and Mast Cells from Human Lung Tissue
Recruitment of eosinophils from the bloodstream into tissue may be associated with altered expression of cellsurface molecules needed to sustain inflammatory and remodeling responses in the local milieu [15] . To investigate whether Siglec-8 expression was altered in tissue, we examined the binding of AK002-G4 in cells derived from dissociated human lung tissue. Using multicolor flow cytometry, we identified immune cell populations routinely found in lung, including eosinophils, mast cells, basophils, neutrophils, lymphocytes, monocytes, and macrophages (Fig. 3a) . Similar to peripheral blood, AK002-G4 only bound to eosinophils and mast cells, and much less to basophils (Fig. 3b, c) . AK002-G4 binding was not detected on other CD45-positive immune cells in the lung (Fig. 3b, c ; online suppl. Fig. S2d, e) . The robust expression of Siglec-8 on eosinophils and mast cells was again confirmed using a commercially available anti-Siglec-8 mAb (online suppl. Fig. S3a ). In addition, AK002-G4 did not bind to CD45-negative cells in human lung tissue ( Fig. 3d, e; online suppl. Fig. S3b) . The Siglec-8-specific AK002-G4 binding profile found in human lung tissue was also consistent with the binding profile using human skin tissue (online suppl. Fig. S3c-e) . These data demonstrate that AK002-G4 binding, and therefore Siglec-8 expression, is specific to eosinophils, mast cells and, to a lower extent, basophils in both human lung and skin tissues.
Tissue-derived cells that expressed Siglec-8 ( Fig. 3b ) were further analyzed to quantify the receptor density of Siglec-8. Lung tissue eosinophils had an average anti-Siglec-8 binding capacity of ∼21,500 per cell and mast cells had an average binding capacity of ∼22,200 per cell (Fig. 3f) . As in peripheral blood, lung basophils displayed markedly lower expression of Siglec-8 than on eosinophils, with an average binding capacity of ∼620 per cell (Fig. 3f) . These data show that eosinophils from lung tissue have a similar number of Siglec-8 receptors as peripheral blood eosinophils, suggesting that Siglec-8 expression is not significantly altered after migration into lung tissue. AK002 is a non-fucosylated, humanized antibody that is specific for Siglec-8 and interacts with CD16a on NK cells. a AK002 specificity and cross-reactivity was examined using a recombinant human Siglec cross-reactivity ELISA. Recombinant Siglecs were coated on the plate overnight at 0.2 µg/mL and AK002 was added at 2 µg/mL for 2 h. The binding kinetics of (b) monovalent AK002 Fabs or (c) full-length IgG AK002 (two-fold dilutions from 12.5 to 0.8 nM) to the Siglec-8 ECD antigen was measured using biolayer interferometry. The following kinetic parameters were determined for the Fab and full-length IgG, respectively: k on = 1.04 × 10 6 
AK002 Depletes Human Eosinophils and Inhibits Mast Cells
AK002 Induces Apoptosis and Has Potent ADCC Activity on Human Eosinophils in vitro
Anti-Siglec-8 mAbs have been shown previously to directly induce apoptosis of isolated human eosinophils, an effect that is enhanced by the activation of eosinophils with IL-5 and other cytokines [4, 5, 7] . Consistent with these reports, AK002 directly induced dose-dependent apoptosis of IL-5-activated eosinophils purified from human blood ( Fig. 4a; online suppl. Fig. S4a ). To determine ADCC-specific cell killing by AK002, human blood eosinophils were co-cultured with NK cells in the absence of eosinophil-activating cytokines to suppress AK002-induced apoptosis. In the presence of purified NK effector cells, AK002 demonstrated rapid ADCC activity against blood eosinophils (Fig. 4b) . In contrast, when AK002-G4 was similarly tested in the presence of NK cells, no ADCC activity was observed (online suppl. Fig. S4b) . Next, human PBL was used to examine the ADCC activity of AK002. Although IL-5 was not included in these cultures, AK002 potently depleted eosinophils in PBL preparations from healthy donors in a dose-dependent manner (EC 50 = 1.9 ng/mL), compared to isotype or AK002-G4 controls ( Fig. 4c; online suppl. Fig. S4c, d) , an activity consistent with ADCC-mediated killing. No reduction was seen in the numbers of other immune cells found in PBL preparations (online suppl. Fig. S4e) , consistent with the selective expression of Siglec-8. These data demonstrate that AK002 has dual activity on human eosinophils: direct induction of apoptosis of IL-5-activated eosinophils via Siglec-8 and induction of potent ADCC activity against eosinophils in the presence of NK cells.
AK002 Reduces Eosinophil Numbers in ex vivo Human Tissue
To begin evaluating the activity of AK002 against tissue eosinophils, we phenotyped eosinophils by flow cytometry to compare surface marker expression between blood and tissue eosinophils. Two cell-surface markers, CD62L and IL-5 receptor were highly expressed on peripheral blood eosinophils but were significantly downregulated on eosinophils from human lung tissue (Fig. 5a, b) [16, 17] . In contrast, Siglec-8 expression was comparable on blood and tissue eosinophils (Fig. 5a, b) . AK002 significantly reduced eosinophils in ex vivo dissociated lung tissue suspensions from multiple donors compared to an isotype control antibody in the absence of exogenous cytokine (Fig. 5c, d ), indicating that AK002 can reduce both blood and tissue eosinophils. AK002 has potent apoptosis-inducing activity and ADCC activity on human eosinophils. a IL-5 activated purified human eosinophils incubated overnight with AK002 (blue) or isotype control antibody (gray) followed by apoptosis detection using Annexin V-PE and 7AAD (mean ± SD of 4 biological replicates). b Purified peripheral blood eosinophils cultured with purified NK cells at a 9: 1 effector:target cell ratio in the presence of 10 μg/mL isotype control or AK002 for 4 h. Cell death determined by lactate dehydrogenase release in cell supernatants (mean ± SD of 3 biological replicates). c PBL from healthy donor incubated overnight with AK002 (blue) or isotype control antibody (gray) and percentage of eosinophils remaining determined (mean ± SD of 3 technical replicates; representative data of 3 donors). In (c), eosinophils were counted by flow cytometry and the percent eosinophils remaining was calculated by normalizing to the percent of CD45+ eosinophils in the isotype control-treated wells to 100%. * p < 0.05; ** p < 0.01. NK, natural killer. Unlike the activity against eosinophils, AK002 did not decrease mast cell numbers in ex vivo dissociated tissue suspensions, consistent with the non-apoptosis-inducing activity of Siglec-8 on mast cells (online suppl. Fig.  S4f ) [4] .
AK002 Depletes Human Eosinophils and Inhibits Mast Cells
mAK002 Inhibits PSA in Humanized Mice
Crosslinking of Siglec-8 on human mast cells previously has been shown to inhibit IgE-mediated mast cell activation in vitro [4, 18] . To examine the in vivo mast cell inhibitory potential of AK002, we tested a mouse precur- sor of AK002 (mAK002), using a humanized strain of mice (NSG-SCF/GM-CSF/IL3 (NSG-SGM3) engrafted with human thymus, liver, and HSC [BLT]), which produces mature, Siglec-8-expressing, human mast cell populations and can generate a PSA response [9] . Siglec-8 expression is restricted to mature mast cells in these mice [9] . As expected, mAK002 has the same binding affinity to Siglec-8 ECD and specificity in human blood as AK002 (online suppl. Fig. S5a, b) . PSA was induced using ch IgEanti-NP and NP-BSA as antigen (Fig. 6a ) [9] . NSG-SGM3 BLT mice sensitized with chIgE-anti-NP and challenged with NP-BSA, but not PBS, demonstrated systemic anaphylaxis as characterized by reduction in rectal temperature and elevated clinical symptom scores (Fig. 6b, c) . mAK002, administered 24-h before IgE sensitization, completely prevented PSA as shown by a lack of change in rectal temperature and symptom scores in treated mice (Fig. 6b, c ). These data demonstrate that mAK002 administration significantly inhibits IgE-mediated mast cell activation in a model of systemic anaphylaxis.
Discussion/Conclusion
Eosinophils and mast cells play pivotal roles in the pathogenesis of many allergic and inflammatory diseases. They can initiate and maintain allergic and inflammatory responses and serve as the primary effector cells leading to both acute tissue responses and long-term tissue damage [19] . Siglec-8 is an attractive therapeutic target because of its selective expression and inhibitory activity on eosinophils and mast cells. Here we characterize AK002, a novel humanized antibody to Siglec-8 with multiple modes of activity against eosinophils and mast cells.
We show that Siglec-8 is expressed at high levels on the surface of eosinophils and mast cells and not on other cells in blood or tissues. Receptor quantification indicated that blood and tissue eosinophils expressed similar levels of Siglec-8 (18,000-21,500), levels comparable to those on lung mast cells (22, 000) . Basophils showed much lower levels of Siglec-8 expression (∼600) in both peripheral blood and dissociated lung tissue. The high Siglec-8 expression on blood and tissue eosinophils is consistent with recently reported levels of Siglec-8 expression on eosinophils from peripheral blood and bronchoalveolar lavage fluid after segmental allergen challenge in subjects with allergic asthma [20] . This is in contrast to the expression of the IL-5 receptor on eosinophils, which is downregulated upon migration from the bloodstream into tissues. Siglec-8 therefore provides an attractive opportunity for targeting both mast cells and eosinophils directly within tissues as well as eosinophils in peripheral blood.
AK002 bound selectively to Siglec-8 with high affinity and showed no detectable binding to other Siglecs by ELI-SA. By flow cytometry, AK002 bound only to eosinophils (and modestly to basophils) in peripheral blood, and to eosinophils and mast cells (and modestly to basophils) in dissociated lung and skin tissues, showing no detectable binding to other hematopoietic or non-hematopoietic cells.
Previous studies have shown that engagement with an anti-Siglec-8 antibody induces apoptosis of cytokineprimed eosinophils mediated by β2-integrin-dependent adhesion and generation of reactive oxygen species [5, 6, 20] . Multiple cytokines have been shown to enhance the sensitivity of eosinophils to Siglec-8-induced apoptosis including IL-5, IL-33, GM-CSF [5] [6] [7] [8] . Consistent with these observations, AK002 induced potent dose-dependent apoptosis of purified IL-5-activated eosinophils.
AK002 was generated as a non-fucosylated IgG1 antibody to increase its binding affinity to FcγRIIIA, (CD16a) and provide enhanced NK cell-mediated ADCC activities in peripheral blood. Indeed, AK002 showed rapid induction of NK cell-mediated ADCC activity against eosinophils in vitro and potent and selective depletion of eosinophils from PBLs without a requirement for exogenous cytokines, consistent with ADCC-mediated cell depletion. The IgG4 form of AK002, which lacks ADCC function, did not induce significant depletion of eosinophils in PBL preparations in the absence of exogenous cytokine, further supporting the importance of CD16a-dependent ADCC for the activity of AK002 against peripheral blood eosinophils.
When using dissociated human lung tissues from multiple donors, AK002 significantly reduced tissue eosinophil numbers, but not mast cells ex vivo. The lack of reduction of lung tissue mast cells after AK002 is consistent with previous studies showing that Siglec-8 ligation does not induce apoptosis in mast cells [4] . These data suggest that the downstream consequences of signaling via Siglec-8 appear to differ between eosinophils and mast cells. Siglec-8 antibodies previously have been shown to kill eosinophils isolated from BAL from asthmatic patients by direct induction of apoptosis without the need for exogenous cytokines [6] . The ability of AK002 to directly induce apoptosis in cytokine-primed eosinophils suggests that this could be the mechanism of lung eosinophil depletion. Thus, AK002 demonstrates 2 modes of killing activity against eosinophils: NK-cell mediated ADCC activity in peripheral blood and direct induction of apoptosis of tissue eosinophils.
The lack of mast cell depletion by AK002 in human lung tissue suggests that ADCC is not highly active in tissue. In support of this, ADCC has been shown to be mediated by NK cells of the CD16 Hi phenotype which are most abundant in the blood [21, 22] . NK cells found in tissue are rare, and even when present are thought to have a CD16 Lo , CD56
Hi phenotype with reduced ADCC activity [21] . These data suggest that ADCC against eosinophils mainly occurs in the blood rather than tissue due to differences in number and function of local NK cell populations. Despite the lack of ADCC-inducing NK cells in lung tissue, AK002 significantly depleted tissue eosinophils, likely via other mechanisms of anti-eosinophilic activity such as apoptosis.
In addition to the depleting activity against eosinophils, anti-Siglec-8 antibodies previously have been shown to inhibit mast cell activation in vitro [4, 18] . To examine if antibody engagement of Siglec-8 can inhibit IgE-mediated mast cell activation in vivo, we used a PSA mouse model which produces human mast cells that populate the peripheral immune system and mucosal tissues [11] . Human mast cells in NSG-SGM3 BLT mice are phenotypically similar to primary human mast cells, expressing Siglec-8, CD117, tryptase, and IgE receptor [9] . These mice developed a human IgE-mediated PSA response following systemic challenge with NP-BSA that was completely prevented by treatment with mAK002. As a result, the dual mechanism of action of AK002 against eosinophils, along with its inhibition of mast cell activation, represents a promising approach for the treatment of allergic and inflammatory diseases.
In summary, we report that Siglec-8 is robustly and selectively expressed on eosinophils and mast cells in human blood and tissue. AK002, a humanized non-fucosylated IgG1 anti-Siglec-8 antibody, selectively binds to human eosinophils, mast cells and, to a lesser extent, basophils, consistent with the restricted expression of Siglec-8. AK002 has potent ADCC and apoptosis-inducing activity against peripheral blood eosinophils and human tissue eosinophils. The antibody also shows inhibitory activity against mast cells in vivo. These findings support the therapeutic potential of AK002 for the treatment of eosinophil and mast cell-related diseases and, pursuant to this, studies are currently underway in mast cell and eosinophilic diseases (eosinophilic gastritis and gastroenteritis, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; e.g., Clinicaltrials.gov identifiers NCT03496571, NCT03436797, NCT03379311, and NCT02808793).
